Cite
HARVARD Citation
Angevin, E. et al. (2017). A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. European journal of cancer. pp. 131-139. [Online].